Targeting NQO1 induces ferroptosis and triggers anti-tumor immunity in immunotherapy-resistant KEAP1-deficient cancers
Drug Resistance Updates · 2024-11 · 77 · 101160
DOI: 10.1016/j.drup.2024.101160 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Resistance Updates, 2024-11. Verfasst von Zhennan Yuan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology Surgery, Harbin Medical University Cancer Hospital, Harbin, China. Hauptthemen laut MEDLINE: Kelch-Like ECH-Associated Protein 1, NAD(P)H Dehydrogenase (Quinone), Ferroptosis, Neoplasms. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: National Natural Science Foundation of China National Outstanding Youth Science Fund Project, Natural Science Foundation of Heilongjiang Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Immunotherapy has revolutionized cancer treatment, yet the efficacy of immunotherapeutic approaches remains limited. Resistance to ferroptosis is one of the reasons for the poor therapeutic outcomes in tumors with Kelch-like ECH-associated protein 1 (KEAP1) mutations. However, the specific mechanisms by which KEAP1-mutant tumors resist immunotherapy are not fully understood. In this study, we showed that the loss of function in KEAP1 results in resistance to ferroptosis. We identified NAD(P)H Quinone Dehydrogenase 1 (NQO1) as a transcriptional target of nuclear factor erythroid 2-related factor 2 (NRF2) and revealed that inducing NQO1-mediated ferroptosis in KEAP1-deficient tumors triggers an antitumor immune cascade. Additionally, it was found that NQO1 protein levels could serve as a candidate biomarker for predicting sensitivity to immunotherapy in clinical tumor patients. We validated these findings in several preclinical tumor models. Overall, KEAP1 mutations define a unique disease phenotype, and targeting its key downstream molecule NQO1 offers new hope for patients with resistance to immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology Surgery, Harbin Medical University Cancer Hospital, Harbin, China.
- Department of Otolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, Hunan, China.
- Department of Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
- Department of Otolaryngology, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
- Department of Respiratory Medicine, Harbin Medical University Cancer Hospital, Harbin, China.
- Department of Oncology Surgery, Harbin Medical University Cancer Hospital, Harbin, China; NHC Key Laboratory of Cell Transplantation, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Prov…
Förderung
- National Natural Science Foundation of China National Outstanding Youth Science Fund Project
- Natural Science Foundation of Heilongjiang Province
- National Natural Science Foundation of China
- Harbin Medical University Cancer Hospital
Zitieren
APA
Yuan, Z., Wang, X., Qin, B., Hu, R., Miao, R., Zhou, Y., Wang, L., & Liu, T. (2024). Targeting NQO1 induces ferroptosis and triggers anti-tumor immunity in immunotherapy-resistant KEAP1-deficient cancers. Drug Resistance Updates, 77, 101160. https://doi.org/10.1016/j.drup.2024.101160
Vancouver
Yuan Z, Wang X, Qin B, Hu R, Miao R, Zhou Y, et al. Targeting NQO1 induces ferroptosis and triggers anti-tumor immunity in immunotherapy-resistant KEAP1-deficient cancers. Drug Resistance Updates. 2024;77:101160. doi:10.1016/j.drup.2024.101160
BibTeX
@article{Yuan2024,
author = {Yuan, Zhennan and Wang, Xueying and Qin, Boyu and Hu, Rulong and Miao, Rui and Zhou, Yang and Wang, Lei and Liu, Tong},
title = {Targeting NQO1 induces ferroptosis and triggers anti-tumor immunity in immunotherapy-resistant KEAP1-deficient cancers},
journal = {Drug Resistance Updates},
year = {2024},
volume = {77},
pages = {101160},
doi = {10.1016/j.drup.2024.101160}
}
EUVIMED